semaglutide fda approved weight loss approves higher dose of Wegovy to increase patient The Digital Semaglutide Program For

New England Journal of Medicine, 384 ,

The once-daily pill also helped 75% of patients who received the highest dose of orforglipron lower their A1C level a measure of blood sugar over time to at or below 6.5%, Lilly said Aug

Semaglutide is typically considered for adults with type 2 diabetes or obesity who haven't achieved weight loss goals through other methods, but it's not appropriate for everyone

But, so, when someone is not simply looking to lose weight, but maybe hyperglycemic and has peripheral insulin resistance, and maybe some of the cardiovascular sequelae, and you do your pooled cohort risk equation like you did for James, and its meaningfully over 7.5, We finally have some strategies that we can implement to make life-saving treatments more efficacious